Dr. Murray Stewart joined Rhythm as Chief Medical Officer in October 2018. He previously served as Head of R&D for Novelion, where he oversaw global medical affairs for Juxtapid® and Myalept®, two marketed products for rare metabolic diseases. Prior to that, Murray was Chief Medical Officer at GlaxoSmithKline (GSK), with global responsibility for patient well-being across the vaccine, pharmaceutical, and consumer business units. During his 18-year career at GSK, Murray held multiple R&D leadership roles, including Chief Medical Officer for the pharmaceutical business, Clinical Head of the Biopharma Unit, and Therapy Area Head for metabolic and cardiovascular diseases. Prior to his tenure with GSK, he worked as a consultant physician and honorary senior lecturer at the Diabetes Center in Newcastle upon Tyne in the UK. Murray began his career as a physician and surgeon. He holds an MD and Bachelor of Medicine from Southampton Medical School and is a Fellow of the Royal College of Physicians.
Rhythm employees and our partners, quite simply, are deeply motivated to make an impactful difference for our patients.